Cover Image
市場調查報告書

的醫藥品的預測與市場分析PharmaPoint:重度憂鬱症 - EU5個國家

Major Depressive Disorder - 5EU Drug Forecast and Market Assessment to 2025

出版商 GlobalData 商品編碼 305471
出版日期 內容資訊 英文 331 Pages
訂單完成後即時交付
價格
Back to Top
的醫藥品的預測與市場分析PharmaPoint:重度憂鬱症 - EU5個國家 Major Depressive Disorder - 5EU Drug Forecast and Market Assessment to 2025
出版日期: 2016年10月05日 內容資訊: 英文 331 Pages
簡介

重度憂鬱症是全球最常見的精神疾病之一。該市場的競爭激烈,有超過30種產品治療藥正在上市。在主要產品的專利到期、最終階段的開發平台產品投入市場的當下,市場正在大大變動中。預測法國市場將會縮小,西班牙則有7個位於最終階段的開發中產品即將上市。

本報告提供EU主要5個國家重度憂鬱症的治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等彙整資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀及亞型
  • 預後
  • QOL

第4章 疾病的管理

  • 症狀和治療概要
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌,選擇性血清素再吸收抑制劑
  • 產品簡介:領導品牌,血清素-去甲腎上腺素再吸收抑制劑
  • 產品簡介:領導品牌,其他抗憂鬱症藥
  • 產品簡介:領導品牌,抗精神藥
  • 其他的治療藥物級

第6章 機會及未滿足需求

  • 概要
  • 更有效的藥物療法
  • 更良好的副作用簡介
  • 效果快速的抗憂鬱效果
  • 個人化醫療的方法

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 其他開發中的藥物

第8章 市場預測

  • 全球
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第9章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC376CFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly's Cymbalta and Otsuka/BMS' Abilify have occurred, and recent launches of Lundbeck/Takeda's Trintellix and Otsuka/Lundbeck's Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.

The recent launch of Lundbeck/Takeda's Trintellix (in 2014) will be the main driver of growth in these markets, as well as the release of four late-stage pipeline drugs during the forecast period. The pipeline drugs will expand the 5EU MDD market substantially from 2018 onwards. Increases in diagnosed prevalent cases of MDD will also drive market growth throughout the 5EU, driven by increased public awareness of depressive disorders, and an increase in the routine screening for depressive disorders.

Scope

  • Overview of MDD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2015-2025.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU MDD market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for MDD.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2015-2025 in 5EU.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 10

2 Introduction 11

  • 2.1 Related Reports 11
  • 2.2 Upcoming Related Reports 12

3 Disease Overview 13

  • 3.1 Etiology and Pathophysiology 13
    • 3.1.1 Etiology 13
    • 3.1.2 Pathophysiology 14
  • 3.2 Classification 17
  • 3.3 Symptoms and Subtypes of Major Depressive Disorder 19
  • 3.4 Prognosis 20
  • 3.5 Quality of Life 20

4 Disease Management 21

  • 4.1 Diagnosis and Treatment Overview 21
    • 4.1.1 Diagnosis 21
    • 4.1.2 Treatment Guidelines 22
    • 4.1.3 Clinical Practice 24
  • 4.2 5EU 28

5 Competitive Assessment 32

  • 5.1 Overview 32
  • 5.2 Selective Serotonin Reuptake Inhibitors 34
    • 5.2.1 Lexapro (Escitalopram) 34
    • 5.2.2 Viibryd (Vilazodone) 42
    • 5.2.3 Other Selective Serotonin Reuptake Inhibitors 46
  • 5.3 Serotonin-Norepinephrine Reuptake Inhibitors 60
    • 5.3.1 Cymbalta (Duloxetine) 60
    • 5.3.2 Effexor (Venlafaxine) 68
    • 5.3.3 Fetzima (Levomilnacipran) 75
    • 5.3.4 Savella (Milnacipran) 81
    • 5.3.5 Pristiq (Desvenlafaxine) 86
  • 5.4 Multimodal Antidepressants 91
    • 5.4.1 Trintellix (Vortioxetine) 91
  • 5.5 Other Antidepressants 100
    • 5.5.1 Bupropion 100
    • 5.5.2 Symbyax (Olanzapine/Fluoxetine) 106
    • 5.5.3 Mirtazapine 111
    • 5.5.4 Monoamine Oxidase Inhibitors 116
    • 5.5.5 Tricyclic Antidepressants 120
  • 5.6 Antipsychotics 124
    • 5.6.1 Abilify (Aripiprazole) 124
    • 5.6.2 Seroquel XR (Quetiapine XR) 131
    • 5.6.3 Rexulti (Brexpiprazole) 136
  • 5.7 Other Therapeutic Classes 142

6 Unmet Need and Opportunity 143

  • 6.1 Overview 143
  • 6.2 New Therapies with Better Efficacy 145
    • 6.2.1 Unmet Need 145
    • 6.2.2 Gap Analysis 147
    • 6.2.3 Opportunity 148
  • 6.3 Improved Safety Profiles 149
    • 6.3.1 Unmet Need 149
    • 6.3.2 Gap Analysis 151
    • 6.3.3 Opportunity 152
  • 6.4 Rapid Onset of Action 154
    • 6.4.1 Unmet Need 154
    • 6.4.2 Gap Analysis 155
    • 6.4.3 Opportunity 157
  • 6.5 Personalized Treatment Approach 158
    • 6.5.1 Unmet Need 158
    • 6.5.2 Gap Analysis 159
    • 6.5.3 Opportunity 160
  • 6.6 Manage Patient Outcome Expectations 162
    • 6.6.1 Unmet Need 162
    • 6.6.2 Gap Analysis 164
    • 6.6.3 Opportunity 165

7 Pipeline Assessment 167

  • 7.1 Overview 167
  • 7.2 Clinical Trial Mapping 167
    • 7.2.1 Clinical Trials by Class of Therapy 167
  • 7.3 Promising Drugs in Clinical Development 168
    • 7.3.1 ALKS-5461 172
    • 7.3.2 Vraylar (Cariprazine) 181
    • 7.3.3 ASC-01 188
    • 7.3.4 AXS-05 191
    • 7.3.5 Esketamine 198
    • 7.3.6 Rapastinel (GLYX-13) 206
    • 7.3.7 Strada (MSI-195) 214
    • 7.3.8 Viotra (Tramadol) 220
  • 7.4 Promising Drugs in Early-Stage Development 227
    • 7.4.1 CGP3466B 227
    • 7.4.2 NSI-189 228
  • 7.5 Other Drugs in Development 229

8 Market Outlook 231

  • 8.1 5EU 231
    • 8.1.1 Forecast 231
    • 8.1.2 Key Events 236
    • 8.1.3 Drivers and Barriers 237

9 Appendix 239

  • 9.1 Bibliography 239
  • 9.2 Abbreviations 285
  • 9.3 Methodology 296
  • 9.4 Forecasting Methodology 296
    • 9.4.1 Diagnosed NSCLC Patients 296
    • 9.4.2 Percent Drug-Treated Patients 297
    • 9.4.3 Drugs Included in Each Therapeutic Class 297
    • 9.4.4 Launch and Patent Expiry Dates 300
    • 9.4.5 General Pricing Assumptions 302
    • 9.4.6 Individual Drug Assumptions 304
    • 9.4.7 Generic Erosion 318
    • 9.4.8 Pricing of Pipeline Agents 318
  • 9.5 Primary Research - KOLs 323
    • 9.5.1 KOLs 323
  • 9.6 About the Authors 327
    • 9.6.1 Analyst 327
    • 9.6.2 Therapy Area Director 327
    • 9.6.3 Epidemiologist 328
    • 9.6.4 Global Head of Healthcare 328
  • 9.7 About GlobalData 330
  • 9.8 Disclaimer 330

List of Tables

  • Table 1: Classification and Criteria of MDD (DSM-IV) and MDE (ICD-10) 18
  • Table 2: Subtypes of Major Depressive Disorder 19
  • Table 3: Severity of Depressive Episodes According to ICD-10 and DSM-IV Diagnostic Criteria 22
  • Table 4: Treatment Guidelines for Major Depressive Disorder 23
  • Table 5: Most-Prescribed Drugs for MDD by Class in the 7MM, 2015 24
  • Table 6: Country Profile - 5EU 31
  • Table 7: Leading Treatments for MDD, 2016 34
  • Table 8: Product Profile - Lexapro 38
  • Table 9: Lexapro/Cipralex SWOT Analysis, 2016 41
  • Table 10: Product Profile - Viibryd 44
  • Table 11: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials 45
  • Table 12: Viibryd SWOT Analysis, 2016 46
  • Table 13: Summary of SSRIs, 2016 50
  • Table 14: SSRIs SWOT Analysis, 2016 60
  • Table 15: Product Profile - Cymbalta 65
  • Table 16: Cymbalta SWOT Analysis, 2016 67
  • Table 17: Product Profile - Effexor 72
  • Table 18: Effexor SWOT Analysis, 2016 74
  • Table 19: Product Profile - Fetzima 78
  • Table 20: Fetzima SWOT Analysis, 2016 80
  • Table 21: Product Profile - Savella 83
  • Table 22: Savella SWOT Analysis, 2016 85
  • Table 23: Product Profile - Pristiq 88
  • Table 24: Pristiq SWOT Analysis, 2016 90
  • Table 25: Product Profile - Trintellix 97
  • Table 26: Trintellix SWOT Analysis, 2016 99
  • Table 27: Product Profile - Bupropion 103
  • Table 28: Bupropion SWOT Analysis, 2016 105
  • Table 29: Product Profile - Symbyax 108
  • Table 30: Symbyax SWOT Analysis, 2016 110
  • Table 31: Product Profile - Mirtazapine 114
  • Table 32: Mirtazapine SWOT Analysis, 2016 116
  • Table 33: MAOIs SWOT Analysis, 2016 120
  • Table 34: TCAs SWOT Analysis, 2016 124
  • Table 35: Product Profile - Abilify 128
  • Table 36: Abilify SWOT Analysis, 2016 130
  • Table 37: Product Profile - Seroquel XR 133
  • Table 38: Seroquel XR SWOT Analysis, 2016 135
  • Table 39: Product Profile - Rexulti 139
  • Table 40: Rexulti SWOT Analysis, 2016 141
  • Table 41: Summary of Minor Therapeutic Classes in MDD, 2016 142
  • Table 42: Unmet Needs and Opportunities in MDD 144
  • Table 43: Promising Drugs in Clinical Development for MDD, 2016 169
  • Table 44: Comparison of Drugs in Development for MDD, 2016 171
  • Table 45: Product Profile - ALKS-5461 176
  • Table 46: SWOT Analysis - ALKS-5461, 2016 180
  • Table 47: Product Profile - Vraylar 184
  • Table 48: SWOT Analysis - Vraylar, 2016 187
  • Table 49: Product Profile - ASC-01 189
  • Table 50: SWOT Analysis - ASC-01, 2016 191
  • Table 51: Product Profile - AXS-05 195
  • Table 52: SWOT Analysis - AXS-05, 2016 197
  • Table 53: Product Profile - Esketamine 202
  • Table 54: SWOT Analysis - Esketamine, 2016 205
  • Table 55: Product Profile - Rapastinel 210
  • Table 56: SWOT Analysis - Rapastinel, 2016 213
  • Table 57: Product Profile - Strada 218
  • Table 58: SWOT Analysis - Strada, 2016 220
  • Table 59: Product Profile - Viotra 223
  • Table 60: SWOT Analysis - Viotra, 2015 226
  • Table 61: Drugs in Development, 2016 230
  • Table 62: Key Events Impacting Sales for MDD Therapies in the 5EU, 2015-2025 236
  • Table 63: MDD Market - Drivers and Barriers in the 5EU, 2015-2025 237
  • Table 64: National Healthcare Authorities and Governmental Drug Pricing Authorities in the 5EU 238
  • Table 65: Key Launch Dates - Part I 300
  • Table 66: Key Launch Dates - Part II 301
  • Table 67: Key Patent Expiries 302

Table 68 Average Body Weight and Surface Area Across the 8MM 303

  • Table 69: Average Cost of Therapy of Alimta in the 8MM 305
  • Table 70: Average Cost of Therapy of Alecensa in the 8MM 306
  • Table 71: Average Cost of Therapy of Avastin 307
  • Table 72: Average Cost of Therapy of Cyramza 307
  • Table 73: Average Cost of Therapy of Gilotrif 308
  • Table 74: Average Cost of Therapy of Iressa 309
  • Table 75: Average Cost of Therapy of Portrazza 310
  • Table 76: Average Cost of Therapy of Tagrisso 311
  • Table 77: Average Cost of Therapy of Tarceva 312
  • Table 78: Average Cost of Therapy of Vargatef 312
  • Table 79: Average Cost of Therapy of Xalkori 313
  • Table 80: Average Cost of Therapy of Zykadia 314
  • Table 81: Average Cost of Therapy of Keytruda 315
  • Table 82: Average Cost of Therapy of Opdivo 316
  • Table 83: Average Cost of Therapy of Tecentriq 317
  • Table 84: Average Cost of Therapy of Conmana 318
  • Table 85: High-Prescribing Physicians Surveyed by Country 326

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 17
  • Figure 2: Disease Management Model for Major Depressive Disorder 25
  • Figure 3: Major Depressive Disorder Treatment Algorithm 27
  • Figure 4: MDD Therapeutics - Phase II and III Clinical Trials in the 7MM, 2016 168
  • Figure 5: MDD Phase II/Phase III Pipeline, 2016 170
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2015-2025 172
  • Figure 7: Clinical and Commercial Positioning of ALKS-5461 179
  • Figure 8: Clinical and Commercial Positioning of Vraylar 186
  • Figure 9: Clinical and Commercial Positioning of ASC-01 190
  • Figure 10: Clinical and Commercial Positioning of AXS-05 196
  • Figure 11: Clinical and Commercial Positioning of Esketamine 204
  • Figure 12: Clinical and Commercial Positioning of Rapastinel 212
  • Figure 13: Clinical and Commercial Positioning of Strada 219
  • Figure 14: Clinical and Commercial Positioning of Viotra 225
  • Figure 15: 5EU Sales by Drug Class for MDD Therapies, 2015 and 2025 233
  • Figure 16: 5EU Sales by Drug Class for MDD Therapies, 2015-2025 234
  • Figure 17: 5EU Sales by Region for MDD Therapies, 2015 and 2025 235
Back to Top